REDD1 Is a Determinant of Low-Dose Metronomic Doxorubicin-Elicited Endothelial Cell Dysfunction through Downregulation of VEGFR-2/3 Expression

Researchers examined the functional role of regulated in development and DNA damage responses 1 (REDD1), an inhibitor of mammalian target of rapamycin complex 1, in low-dose metronomic chemotherapy-mediated endothelial cell dysfunction.